Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Basem M William

Showing results (21-30 of 59) with videos related to

Pageof 6
Sort By:
Polish Journal of Pharmacology|November 3, 2004
Acetylator phenotyping in patients with malignant lymphomas, using caffeine as the metabolic probeBasem M William, Ahmed M Abdel-tawab, Essam A Hassan, et al.
Revista Brasileira De Hematologia E Hemoterapia|July 18, 2014
Transmission of lupus anticoagulant by allogeneic stem cell transplantationMira Romany Massoud, Basem M William, Katrina Harrill, et al.
Clinical Lymphoma, Myeloma & Leukemia|March 14, 2025
Narrowing of the Racial Disparities Gap in Survival of Patients With Mycosis Fungoides: A Longitudinal Analysis of the SEER DatabaseBritney Le, Noha Soror, Hamid D Ismail, et al.
Hematology (Amsterdam, Netherlands)|July 16, 2015
Fasudil, a clinically safe ROCK inhibitor, decreases disease burden in a Cbl/Cbl-b deficiency-driven murine model of myeloproliferative disordersBasem M William, Wei An, Dan Feng, et al.
Clinical Lymphoma, Myeloma & Leukemia|June 19, 2013
Impact of conditioning regimen on outcome of 2-year disease-free survivors of autologous stem cell transplantation for Hodgkin lymphomaBasem M William, Fausto R Loberiza, Victoria Whalen, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|January 18, 2014
Phase I/II study of bortezomib-BEAM and autologous hematopoietic stem cell transplantation for relapsed indolent non-Hodgkin lymphoma, transformed, or mantle cell lymphomaBasem M William, Mary S Allen, Fausto R Loberiza, et al.
Clinical Lymphoma, Myeloma & Leukemia|September 2, 2015
Trends and Disparities in Cardiovascular Mortality Among Survivors of Hodgkin LymphomaSadeer G Al-Kindi, Ghaith F Abu-Zeinah, Chang H Kim, et al.
Cancer Management and Research|December 8, 2021
Cytopenias After CD19 Chimeric Antigen Receptor T-Cells (CAR-T) Therapy for Diffuse Large B-Cell Lymphomas or Transformed Follicular Lymphoma: A Single Institution ExperienceAndrew Schaefer, Ying Huang, Adam Kittai, et al.
Clinical Lymphoma, Myeloma & Leukemia|February 23, 2020
A Phase II Study of Midostaurin and 5-Azacitidine for Untreated Elderly and Unfit Patients With FLT3 Wild-type Acute Myelogenous LeukemiaBenjamin K Tomlinson, Molly M Gallogly, Donna M Kane, et al.
Oncotarget|November 8, 2017
Phase I clinical trial of the base excision repair inhibitor methoxyamine in combination with fludarabine for patients with advanced hematologic malignanciesPaolo F Caimi, Brenda W Cooper, Basem M William, et al.
Pageof 6

Showing results (21-30 of 59) with videos related to

Sort By:
Pageof 6
Polish Journal of Pharmacology|November 3, 2004
Acetylator phenotyping in patients with malignant lymphomas, using caffeine as the metabolic probeBasem M William, Ahmed M Abdel-tawab, Essam A Hassan, et al.
Revista Brasileira De Hematologia E Hemoterapia|July 18, 2014
Transmission of lupus anticoagulant by allogeneic stem cell transplantationMira Romany Massoud, Basem M William, Katrina Harrill, et al.
Clinical Lymphoma, Myeloma & Leukemia|March 14, 2025
Narrowing of the Racial Disparities Gap in Survival of Patients With Mycosis Fungoides: A Longitudinal Analysis of the SEER DatabaseBritney Le, Noha Soror, Hamid D Ismail, et al.
Hematology (Amsterdam, Netherlands)|July 16, 2015
Fasudil, a clinically safe ROCK inhibitor, decreases disease burden in a Cbl/Cbl-b deficiency-driven murine model of myeloproliferative disordersBasem M William, Wei An, Dan Feng, et al.
Clinical Lymphoma, Myeloma & Leukemia|June 19, 2013
Impact of conditioning regimen on outcome of 2-year disease-free survivors of autologous stem cell transplantation for Hodgkin lymphomaBasem M William, Fausto R Loberiza, Victoria Whalen, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|January 18, 2014
Phase I/II study of bortezomib-BEAM and autologous hematopoietic stem cell transplantation for relapsed indolent non-Hodgkin lymphoma, transformed, or mantle cell lymphomaBasem M William, Mary S Allen, Fausto R Loberiza, et al.
Clinical Lymphoma, Myeloma & Leukemia|September 2, 2015
Trends and Disparities in Cardiovascular Mortality Among Survivors of Hodgkin LymphomaSadeer G Al-Kindi, Ghaith F Abu-Zeinah, Chang H Kim, et al.
Cancer Management and Research|December 8, 2021
Cytopenias After CD19 Chimeric Antigen Receptor T-Cells (CAR-T) Therapy for Diffuse Large B-Cell Lymphomas or Transformed Follicular Lymphoma: A Single Institution ExperienceAndrew Schaefer, Ying Huang, Adam Kittai, et al.
Clinical Lymphoma, Myeloma & Leukemia|February 23, 2020
A Phase II Study of Midostaurin and 5-Azacitidine for Untreated Elderly and Unfit Patients With FLT3 Wild-type Acute Myelogenous LeukemiaBenjamin K Tomlinson, Molly M Gallogly, Donna M Kane, et al.
Oncotarget|November 8, 2017
Phase I clinical trial of the base excision repair inhibitor methoxyamine in combination with fludarabine for patients with advanced hematologic malignanciesPaolo F Caimi, Brenda W Cooper, Basem M William, et al.
Pageof 6